A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Summary

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.

Timeline

Start

2021-12-15

Primary completion

2024-11

Completion

2025-10

Outcome

Outcome not reported

Stopped: “Temporary operational pause; no safety concerns.”

Drugs

Indications